We have been studying in situ vaccination strategies using tumor-selective oncolytic vaccinia viruses carrying a series of immunomodulator(s), and previously demonstrated that intratumoral expression of IL-7 together with IL-12 contributed to a higher rate of complete regression (CR) of poorly immunogenic tumors [15]. The gene discussed is IL7; the disease is neoplasm.